The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease
The DOI matches its Crossref record; 14 of the 15 references it cites were found in a registry or an index.
Abstract
Background Although treatment of myocardial overload effectively reduces death from progression of heart failure, it is not known whether the retardation of progressive coronary artery disease obtained with lipid lowering treatment will prevent the onset and consequences of heart failure in patients without previous symptoms of heart failure.Methods and results In the Scandinavian Simvastatin Survival Study, 4444 patients with coronary heart disease without evidence of heart failure were randomized to placebo (n = 2223) or simvastatin 20-40 mg (n = 2221) and followed for more than 5 years. Among the patients who received placebo, 228 (10.3%) were diagnosed with heart failure during follow-up evaluation compared with 184 (8.3%) of patients who received simvastatin (P < .015). Mortality was 31.9% in the placebo group and 25.5% in the simvastatin group among patients who developed heart failure. These compare with 9.2 and 6.6%, respectively, among non-heart failure patients. There were 45 hospitalizations because of acute heart failure in the placebo group and 23 in the simvastatin group (NS). Patients who developed heart failure were more likely to have suffered a recurrent myocardial infarction and have a history of diabetes, peripheral artery disease, and hypertension than patients who did not develop congestive heart failure.Conclusion Long-term prevention with simvastatin reduces the occurrence of heart failure in a cohort of patients with coronary heart disease without previous evidence of congestive heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a pre-specified analysis, a significant 28% relative risk reduction in MACE was observed among patients who underwent PCI (65% of all patients).”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [443]
In the citing paper
“The authors found no significant treatment benefit in the overall study population.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [443]
In the citing paper
“The benefit was even more pronounced (46% relative risk reduction) in a post hoc analysis including 865 ST-elevation MI (STEMI) patients undergoing reperfusion by primary PCI [443].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [443]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9-45% in patients with CAD.22,180”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [180]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9-45% in patients with CAD. 368,369”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [368]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citationThe SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
Swedberg, K., & Kjekshus, J. (1988) · The American Journal of Cardiology · doi:10.1016/s0002-9149(88)80087-0 · Cited by 3,762
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Fuster, V (1994) · Circulation · doi:10.1161/01.cir.90.4.2126 · Cited by 848
Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin survival study (4S)
Kjekshus, J., & Pedersen, T. R. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80473-1 · Cited by 172
Self-citationBrodie, B. R., Stuckey, T., Kissling, G. E., Hansen, C. J., Weintraub, R. A., & Kelly, T. A. F. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)00152-0 · Cited by 78
Research works printed but not linked: 1
- Meredith, 1993, Role of impaired endothelium-dependent vasodilatation in ischemic manifestations of coronary artery disease, Circulation, 87, V56
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citation
Metadata
- Authors
- Kjekshus, J., Pedersen, T. R., Olsson, A. G., Færgeman, O., & Pyörälä, K.
- Affiliations
- Linköping University (SE)
- Corresponding author
- Kjekshus, John
- Venue
- Journal of Cardiac Failure
- Publisher
- Elsevier BV
- Published
- 1997-12
- Volume
- 3
- Issue
- 4
- Pages
- 249-254
- ISSN
- 1071-9164 (ISSN-L)
- OpenAlex
- W2091243061
- Cited by
- 386
- References
- 15
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 7 · 2018: 3 · 2017: 6 · 2016: 16 · 2015: 10 · 2014: 3 · 2013: 19 · 2012: 8
- FWCI
- 7.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Cardiac Failure (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- simvastatin, heart failure prevention, coronary artery disease, lipid-lowering therapy, statins, heart failure incidence, mortality, Scandinavian Simvastatin Survival Study, heart failure risk
- MeSH terms
- Adult, Aged, Anticholesteremic Agents, Coronary Disease, Heart Failure, Humans, Middle Aged, Retrospective Studies, Multicenter Studies as Topic, Survival Analysis, Randomized Controlled Trials as Topic, Disease Progression, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. https://app.cochat.ai/papers/10.1016/s1071-9164(97)90022-1
- The paper
- Kjekshus, J., Pedersen, T. R., Olsson, A. G., Færgeman, O., & Pyörälä, K. (1997). The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. Journal of Cardiac Failure. https://doi.org/10.1016/s1071-9164(97)90022-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.